Grab A 5% Yield With GlaxoSmithKline plc, Standard Life Plc And Tate & Lyle PLC

These 3 stocks offer stunning income prospects: GlaxoSmithKline plc (LON: GSK), Standard Life Plc (LON: SL) and Tate & Lyle PLC (LON: TATE).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

With interest rates likely to remain low over the coming years, the ability to achieve a 5% yield on high quality companies is highly enticing. That’s especially the case when the prospects for a number of those stocks are upbeat and also because their future dividend growth could easily beat inflation.

Positive outlook

For example, Standard Life (LSE: SL) currently yields 5.4% and with the asset manager having a strong track record of increasing dividends per share, the outlook for future dividend growth is very positive. Shareholder payouts have risen by around 7.3% per annum during the last five years, which is considerably higher than the rate of inflation during that time. And with dividends being covered 1.4 times by profit, there’s clear scope for further rises moving forward.

In fact, Standard Life’s bottom line is expected to increase by 9% in 2017 and this should allow it to raise dividends by around 7.7%. This could act as a positive catalyst on the company’s share price and allow it to reverse the 35% fall over the last year. With Standard Life trading on a price-to-earnings growth (PEG) ratio of 1.3, it seems to offer excellent value for money, too.

Should you invest £1,000 in Royal Dutch Shell Plc right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Royal Dutch Shell Plc made the list?

See the 6 stocks

Sweet pick

Also having a yield above 5% is Tate & Lyle (LSE: TATE). Although the last few years have been challenging for the business due to a variety of factors, including commodity pricing pressure and increased competition for the company’s products, it’s expected to turn things around in 2017 and 2018. In fact, its bottom line is forecast to rise by 10% in the next financial year, and by a further 5% in the year following that.

This turnaround could act as a positive catalyst not only on Tate & Lyle’s share price, but also on its dividend payments. With the company’s shareholder payouts being covered 1.3 times by profit, there’s scope to increase dividends at a similar pace to profit growth over the medium-to-long term. While further challenges could lie ahead, Tate & Lyle now seems to have a better organised supply chain through which to move forward, while its price-to-earnings (P/E) ratio of 15.3 indicates that there remains substantial upward rerating potential.

Non-cyclical star

Meanwhile, GlaxoSmithKline (LSE: GSK) continues to be one of the highest yielding shares in the FTSE 100. Its yield stands at 5.7% and while dividend growth is expected to be lacking over the next couple of years, GlaxoSmithKline has the potential to raise dividends at a rapid rate over the long term.

A key reason for that is the changes the company is making to its business model. It’s seeking to drive through over £1bn in cost savings in the next few years and this could help to improve profitability. Furthermore, GlaxoSmithKline’s dividend growth should be positively impacted by its impressive and diversified pipeline of new drugs that have the potential to reinvigorate its bottom line following a period of rather lacklustre growth.

As well as a top-notch yield and upbeat dividend growth prospects, GlaxoSmithKline remains a relatively defensive option. It has a beta of 0.9, which indicates that its shares should be less volatile than the wider index, while its lack of cyclicality means that its shares could rise even if the macroeconomic outlook remains uncertain.

Pound coins for sale — 31 pence?

This seems ridiculous, but we almost never see shares looking this cheap. Yet this Share Advisor pick has a price/book ratio of 0.31. In plain English, this means that investors effectively get in on a business that holds £1 of assets for every 31p they invest!

Of course, this is the stock market where money is always at risk — these valuations can change and there are no guarantees. But some risks are a LOT more interesting than others, and at The Motley Fool we believe this company is amongst them.

What’s more, it currently boasts a stellar dividend yield of around 10%, and right now it’s possible for investors to jump aboard at near-historic lows. Want to get the name for yourself?

See the full investment case

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of GlaxoSmithKline, Standard Life, and Tate & Lyle. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

We think earning passive income has never been easier

Do you like the idea of dividend income?

The prospect of investing in a company just once, then sitting back and watching as it potentially pays a dividend out over and over?

If you’re excited by the thought of regular passive income payments, as well as the potential for significant growth on your initial investment…

Then we think you’ll want to see this report inside Motley Fool Share Advisor — ‘5 Essential Stocks For Passive Income Seekers’.

What’s more, today we’re giving away one of these stock picks, absolutely free!

Get your free passive income stock pick

More on Investing Articles

Calendar showing the date of 5th April on desk in a house
Investing Articles

Here’s how a £20k ISA could produce £1,580 of passive income in the next year

A Stocks and Shares ISA stuffed with dividend shares can be a lucrative source of passive income. Christopher Ruane explains…

Read more »

Investing Articles

Prediction: 12 months from now, £5,000 invested in Tesla stock could be worth…

Tesla stock has endured a miserable year so far, falling by 29%. Muhammad Cheema takes a look at how it…

Read more »

Investing Articles

See what £10,000 invested in Tesla shares at their mid-December peak is worth today 

As the world absorbs the full scale of Donald Trump's tariffs, Tesla shares are reeling. Investors who bought the stock…

Read more »

Hand flipping wooden cubes for change wording" Panic " to " Calm".
Dividend Shares

2 ‘safe’ LSE dividend stocks to consider as global markets sell off

As global markets experience high levels of volatility due to economic uncertainty, investors are piling into these ‘safe-haven’ dividend stocks.

Read more »

Investing Articles

US stock market rout: an unmissable opportunity for investors?

His tech-heavy portfolio has been smashed by Trump’s tariffs. However, Dr James Fox believes there could be some opportunities in…

Read more »

Investing Articles

After a 13% ‘Trump tariff’ fall, is the Barclays share price too cheap to miss?

Does the Barclays share price fall mean we should all panic and run screaming from the stock market? Nah, of…

Read more »

Mature Caucasian woman sat at a table with coffee and laptop while making notes on paper
Investing Articles

2 investment trusts to consider for a Stocks and Shares ISA

These two investment trusts have a different focus -- but our writer sees both as worth considering, one more for…

Read more »

Investing Articles

Deutsche Bank reiterates Buy rating on 9.6% yielding FTSE 250 stock that was “most shorted in UK”

Our writer investigates why a major broker remains optimistic about a FTSE 250 stock that was once the most shorted…

Read more »